

Boston Scientific

Boston Scientific and Angiotech Win Patent Infringement Case Against Conor in the Netherlands

Court Orders Injunction and Damages

PRNewswire-FirstCall

NATICK, Mass.

(NYSE:BSX)

NATICK, Mass., Jan. 17 /[PRNewswire-FirstCall](#)/ -- Boston Scientific Corporation (NYSE: BSX) announced today that it and Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP) won a patent infringement case against Conor Medsystems, Inc. (NASDAQ: CONR) in the Netherlands. The District Court in The Hague found Conor's CoStar™ paclitaxel stent to infringe a key claim of the Dutch version of Angiotech's European paclitaxel stent patent, and upheld the validity of that claim. This key claim of the European patent, the U.K. version of which was revoked by a U.K. court yesterday, has now been upheld twice by The Hague District Court in two separate actions, the first of which was decided in May of 2006. The patent, which is valid and enforceable in all designated European jurisdictions except the U.K., is part of a worldwide patent portfolio exclusively licensed to Boston Scientific.

The Court granted Boston Scientific and Angiotech an injunction against Conor, prohibiting the company from selling the infringing CoStar paclitaxel stent in the Netherlands. The Court also ordered Conor to pay damages and/or surrender profits resulting from the infringement.

"We are pleased the Dutch Court upheld the validity of this key claim of Angiotech's European patent and found that Conor's stent infringes," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "This decision reaffirms the strength of Angiotech's worldwide paclitaxel stent intellectual property portfolio."

The decision is appealable by Conor.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

<http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Dan Brennan
508-650-8538 (office)
617-459-2703 (mobile)
Investor Relations
Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541, or mobile, +1-508-667-5165, or Dan Brennan, Investor Relations, +1-508-650-8538, or mobile, +1-617-459-2703, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/news-releases?item=58930>